Xenon Pharmaceuticals (NASDAQ:XENE) & Cardium Therapeutics (OTCMKTS:CRXM) Critical Comparison

Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) and Cardium Therapeutics (OTCMKTS:CRXM – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends.

Earnings and Valuation

This table compares Xenon Pharmaceuticals and Cardium Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

Institutional & Insider Ownership

95.4% of Xenon Pharmaceuticals shares are held by institutional investors. 2.9% of Xenon Pharmaceuticals shares are held by insiders. Comparatively, 49.8% of Cardium Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Xenon Pharmaceuticals and Cardium Therapeutics, as reported by MarketBeat.com.

Xenon Pharmaceuticals currently has a consensus target price of $77.13, suggesting a potential upside of 29.14%. Given Xenon Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Xenon Pharmaceuticals is more favorable than Cardium Therapeutics.

Profitability

This table compares Xenon Pharmaceuticals and Cardium Therapeutics’ net margins, return on equity and return on assets.

Summary

Xenon Pharmaceuticals beats Cardium Therapeutics on 5 of the 8 factors compared between the two stocks.

About Xenon Pharmaceuticals

(Get Free Report)

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

About Cardium Therapeutics

(Get Free Report)

Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.